(Finance) – Svas Biosanaa company listed on Euronext Growth Milan since December 2021 and active in the production of medical devices for healthcare facilities, recorded a consolidated turnover preliminary financial year 2021 equal to 81.1 million eurosan increase of 6.6% compared to the turnover of 76 million euros in 2020. “The year 2021 was a particularly important year for SVAS characterized by various strategic choices including the stock exchange listing on the EGM market and the significant strengthening of the competitive position “, commented theAD Umberto Perillo.
“Also 2022 has started with significant orders already communicated to the market and with a backlog of orders in the portfolio of all respect – added Perillo – In 2022 we expect important challenges, the projects in the pipeline are numerous and will further strengthen the structure in its wholeness for making Svas more dynamic and ready to intercept new opportunities on the domestic and international market that will arise, generating further value for the benefit of all stakeholders “.